{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypothyroidism/prescribing-information/levothyroxine/","result":{"pageContext":{"chapter":{"id":"ee5ac1fb-6ba7-5e52-9861-d62637c03bf0","slug":"levothyroxine","fullItemName":"Levothyroxine","depth":2,"htmlHeader":"<!-- begin field d9c12d71-778a-464b-a09c-b52d84980a0e --><h2>Levothyroxine</h2><!-- end field d9c12d71-778a-464b-a09c-b52d84980a0e -->","summary":"","htmlStringContent":"<!-- begin item e7104f25-b328-4032-9a41-723525f05a4e --><!-- end item e7104f25-b328-4032-9a41-723525f05a4e -->","topic":{"id":"f1d76bc1-c8dd-515b-a709-48c70c829658","topicId":"ebfc5032-6653-4b11-895c-5080f933e861","topicName":"Hypothyroidism","slug":"hypothyroidism","lastRevised":"Last revised in August 2020","chapters":[{"id":"cf0a606b-f582-5671-a84d-a1a3a12b7180","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"795eb9d9-4e15-51f6-81f4-7cc1b69ca74e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a8d7a846-dfa6-5db5-ba95-fb161fd48c6e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d8567cc1-0642-5e9e-ad6c-8ca4abf5fa6e","slug":"changes","fullItemName":"Changes"},{"id":"c5e99cd1-e0c7-5efd-84bb-15bac6122b1d","slug":"update","fullItemName":"Update"}]},{"id":"2b8464ae-3182-517a-85be-6acc656616c5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"17d5ebf3-bdca-50d2-a4f5-245d191f4973","slug":"goals","fullItemName":"Goals"},{"id":"9162c6a3-edc4-5319-9418-04b2cb656ce6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2ae5c1d9-638e-52fa-b738-9561cd11b0ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fec82ae-e144-56a7-b1e8-8744c35e227e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"610f052f-83a2-5b06-b5e6-4aa272ef73a6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a578bde3-0d84-54f7-814d-18ed38e6038a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"66bb9b4f-4de2-5da7-aba1-ec9bff4b2454","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4b8f382f-673d-5804-8291-438e21e32790","slug":"definition","fullItemName":"Definition"},{"id":"ef0d96cd-207c-5814-93cf-c96870e2251d","slug":"causes","fullItemName":"Causes"},{"id":"09adb285-1d01-592a-9443-295b45c7d78b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9bfb88d8-8d33-53a3-8d0e-1b202457fb2e","slug":"complications","fullItemName":"Complications"},{"id":"5ff1ef9f-bb77-5feb-bd5a-12d7b43cca9d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"cfe582c4-479a-5d44-b893-ac46a1a80b29","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6884c3db-6165-566b-a4ca-3e933de77714","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"42799fb8-7252-541e-9af1-27ebc28710b7","slug":"assessment","fullItemName":"Assessment"},{"id":"e850b740-b6cf-55a7-aed8-7372b7f13b05","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"d817ab4c-e7a3-582a-94fa-fcffd9c2d4f6","slug":"screening","fullItemName":"Screening"}]},{"id":"b377a2c4-68d7-573f-912f-123b99d0aba1","fullItemName":"Management","slug":"management","subChapters":[{"id":"daacd844-c78f-5626-a2ea-93077f98f729","slug":"overt-hypothyroidism-non-pregnant","fullItemName":"Scenario: Overt hypothyroidism (non-pregnant)"},{"id":"e358d249-a2f3-5a06-b301-2119af9ae164","slug":"subclinical-hypothyroidism-non-pregnant","fullItemName":"Scenario: Subclinical hypothyroidism (non-pregnant)"},{"id":"9e4d552e-5fb3-571b-b14a-fec340b943f0","slug":"preconception-or-pregnant","fullItemName":"Scenario: Preconception or pregnant"},{"id":"611f3939-9d39-5545-b225-f9b33fdb095e","slug":"postpartum","fullItemName":"Scenario: Postpartum"}]},{"id":"7b2d6d51-4029-5c06-8789-30e0056076fa","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ee5ac1fb-6ba7-5e52-9861-d62637c03bf0","slug":"levothyroxine","fullItemName":"Levothyroxine"}]},{"id":"2aaf1754-ba79-5b47-b2a5-74fe8f6af4da","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7669c894-3a85-55c7-b689-cb4b710a838a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"840d7de5-8c31-5696-9de6-c80ce1bbfec7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"299c20bf-2a22-5681-99ad-5f02f1395969","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dd3df39b-4a5c-5416-af8d-dcdbf46bd255","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a88d4431-778a-5793-9557-9f806339a95b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1987302d-f600-55e0-a528-d3486c49048e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a49e5d2f-75e4-5219-a4d6-fd4a5595a776","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7b2d6d51-4029-5c06-8789-30e0056076fa","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"624e4843-9981-53e2-a271-088d2799d1d5","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 54f95a49-10d8-42f6-9e63-b4ea88bae12b --><h3>Contraindications and cautions</h3><!-- end field 54f95a49-10d8-42f6-9e63-b4ea88bae12b -->","summary":"","htmlStringContent":"<!-- begin item e48c1b6c-6790-4b40-ba7d-5b374b27737d --><!-- begin field 8a6c7f45-392b-4e08-a800-19a80e8cd88b --><ul><li><strong>Do not prescribe levothyroxine if there is suspected:</strong><ul><li>Thyrotoxicosis. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hyperthyroidism/\">Hyperthyroidism</a> for more information.</li><li>Adrenal gland disorder or insufficiency.</li><li>Hypersensitivity to any component.</li><li>Hereditary problems of galactose intolerance, the Lapp lactose deficiency, or glucose-galactose malabsorption.</li></ul></li><li><strong>Prescribe levothyroxine with caution in people:</strong><ul><li>With panhypopituitarism or a predisposition to adrenal insufficiency — adrenal insufficiency should be corrected with glucocorticoid therapy under a specialist before initiating levothyroxine, to prevent precipitation of acute adrenal crisis. </li><li>With cardiovascular disorders (such as hypertension, angina, heart failure, or myocardial infarction) — a baseline ECG may help distinguish underlying myocardial ischaemia from changes due to hypothyroidism.</li><li>With longstanding hypothyroidism — levothyroxine should be introduced very gradually to avoid any sudden increase in metabolic demands. </li><li>With diabetes mellitus — treatment with levothyroxine may increase blood glucose levels. The dose of anti-diabetic drugs may need to be increased. </li><li>Who are breastfeeding or pregnant — levothyroxine therapy should be supervised by an endocrinology specialist. </li><li>Who are elderly — levothyroxine therapy should be introduced gradually to avoid any sudden increase in metabolic demands. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 8a6c7f45-392b-4e08-a800-19a80e8cd88b --><!-- end item e48c1b6c-6790-4b40-ba7d-5b374b27737d -->","subChapters":[]},{"id":"c17d9834-4788-5dd0-a73f-1c92ec5b50da","slug":"initiation-titration","fullItemName":"Initiation and titration","depth":3,"htmlHeader":"<!-- begin field 66a3a845-65e9-43e8-9886-a948f3b65ef5 --><h3>Initiation and titration</h3><!-- end field 66a3a845-65e9-43e8-9886-a948f3b65ef5 -->","summary":"","htmlStringContent":"<!-- begin item 094f295c-914f-4e99-9e94-5970b38d4c47 --><!-- begin field 4b8de0ad-bae4-467e-9fe7-4cf723ce6546 --><p><strong>The dose of levothyroxine (LT4) should be individualized on the basis of clinical response and thyroid function test (TFT) results. Treatment must be monitored regularly to determine an adequate dose and to avoid both under- and over-treatment.</strong></p><ul><li><strong>The NICE clinical guideline recommends:</strong><ul><li>Consider starting LT4 at a dosage of 1.6 micrograms per kilogram of bodyweight per day (rounded to the nearest 25 micrograms) for adults under 65 years of age with primary hypothyroidism and no history of cardiovascular disease.</li><li>Consider starting LT4 at a dosage of 25–50 micrograms per day with titration for adults aged 65 years and over, and adults with a history of cardiovascular disease.</li></ul></li><li><strong>The British National Formulary (BNF) recommends:</strong><ul><li>For adults aged 18–49 years — initially 50–100 micrograms once daily; adjusted in steps of 25–50 micrograms every 3–4 weeks, adjusted according to response; maintenance 100–200 micrograms once daily.</li><li>For adults aged 50 years and over, with cardiovascular disease, or severe hypothyroidism — initially 25 micrograms once daily; adjusted in steps of 25 micrograms every 4 weeks, adjusted according to response; maintenance 50–200 micrograms once daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">NICE, 2019</a>] </p><!-- end field 4b8de0ad-bae4-467e-9fe7-4cf723ce6546 --><!-- end item 094f295c-914f-4e99-9e94-5970b38d4c47 -->","subChapters":[]},{"id":"a804e588-b573-510a-a06a-0464f99d05e5","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 39422870-5a00-4501-bd62-7f6dc2df1a13 --><h3>Adverse effects</h3><!-- end field 39422870-5a00-4501-bd62-7f6dc2df1a13 -->","summary":"","htmlStringContent":"<!-- begin item 965e8a93-2d7f-4f1b-99e4-9eed4dc82617 --><!-- begin field 12a89d85-62e5-456a-9d94-a04d938af2cc --><p><strong>Adverse effects of levothyroxine (LT4) usually occur with excessive dosage and usually stop on reduction of dosage or withdrawal of treatment for a few days. They include:</strong></p><ul><li>Gastrointestinal — such as diarrhoea and vomiting.</li><li>Cardiovascular — such as angina, arrhythmias, palpitations, and tachycardia.</li><li>Immunological — such as hypersensitivity reactions (including rash, pruritus, urticaria, and oedema).</li><li>Metabolic — such as weight loss.</li><li>Musculoskeletal — such as arthralgia and muscle weakness.</li><li>Neurological — such as anxiety, tremor, restlessness, excitability, insomnia.</li><li>Psychiatric — may induce mania.</li><li>Reproductive — menstrual irregularities.</li><li>General — such as headache, flushing, sweating, fever, heat intolerance.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 12a89d85-62e5-456a-9d94-a04d938af2cc --><!-- end item 965e8a93-2d7f-4f1b-99e4-9eed4dc82617 -->","subChapters":[]},{"id":"6b530d21-e845-550f-b81b-832f49477b47","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 41cd0095-9077-4a4b-bfcd-3476e28bf30a --><h3>Drug interactions</h3><!-- end field 41cd0095-9077-4a4b-bfcd-3476e28bf30a -->","summary":"","htmlStringContent":"<!-- begin item 7ca752ba-a2f3-4bdd-8a82-c2eaea315a96 --><!-- begin field 1a2ac1db-d43c-4341-a268-91abd976c786 --><ul><li><strong>Possible drug interactions with levothyroxine include:</strong><ul><li><strong>Amiodarone</strong> — serum concentrations of thyroid hormones can be affected by amiodarone, and close monitoring by a specialist is recommended. Amiodarone has a long half-life and drug interactions may occur several weeks (or even months) after it is stopped.</li><li><strong>Lipid-regulating drugs</strong> — colestyramine and colestipol can reduce absorption of levothyroxine when taken together. Advise that levothyroxine should be taken one hour before or 4–6 hours after taking colestyramine or colestipol.</li><li><strong>Antacids</strong> — calcium carbonate or antacids containing aluminium and magnesium may reduce the absorption of levothyroxine. Advise that separation of doses by at least four hours may minimize the risk of interaction.</li><li><strong>Antibacterials</strong> — rifampicin enhances thyroid hormone metabolism and may increase levothyroxine requirements. Monitor thyroid function tests and adjust the dosage of levothyroxine accordingly.</li><li><strong>Anticancer drugs</strong> — plasma concentration of levothyroxine may be reduced by imatinib.</li><li><strong>Oral anticoagulants</strong> — levothyroxine may enhance the effects of anticoagulants such as coumarins (for example warfarin) or phenindione; concomitant administration may require a reduction in oral anticoagulant dose. Changes in clinical condition, particularly any associated with liver disease, intercurrent illness, or drug administration, requires more frequent testing of international normalized ratio (INR). Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control. Adjust the warfarin dose accordingly.</li><li><strong>Antidepressants</strong> — the effects of levothyroxine may be decreased by concomitant treatment with sertraline. Antidepressant response to tricyclics can be accelerated, concomitant administration may precipitate cardiac arrhythmias.</li><li><strong>Antidiabetic drugs</strong> — treatment with levothyroxine may increase blood glucose levels; therefore the requirements for insulin or oral antidiabetic drugs may be increased.</li><li><strong>Antiepileptic drugs</strong> — carbamazepine, barbiturates (including phenobarbital), phenytoin, and primidone can accelerate levothyroxine metabolism and increase LT4 requirements.</li><li><strong>Beta-blockers</strong> — may decrease peripheral conversion of levothyroxine to triiodothyronine. Levothyroxine accelerates metabolism of propranolol.</li><li><strong>Cardiac glycosides</strong> — people with hypothyroidism may be initially sensitive to digitalis, but may need a gradually increasing dose of cardiac glycosides as treatment with levothyroxine progresses.</li><li><strong>Iron salts</strong> — ferrous sulphate reduces absorption of levothyroxine. Advise that the drugs should be taken at least two hours apart to reduce the risk of this interaction.</li><li><strong>Sex hormones</strong> — oestrogens increase and androgens decrease serum thyroxine-binding globulin; thyroid hormone requirements may be increased during oestrogen therapy and reduced during androgen therapy. Thyroid function should be monitored regularly. Oestrogens in oral contraceptives may increase LT4 requirements.</li><li><strong>Sympathomimetics</strong> (such as midodrine)<strong> </strong>— effects may be enhanced by levothyroxine.</li><li><strong>Gastrointestinal ulcer-healing drugs</strong> — sucralfate or cimetidine and proton pump inhibitors may reduce the absorption of levothyroxine.</li><li><strong>Orlistat</strong> may decrease levothyroxine absorption which may result in hypothyroidism. Monitor for changes in thyroid function.</li><li><strong>Ritonavir</strong> — the manufacturers summary of product characteristics explains a potential interaction between ritonavir and levothyroxine,  leading to reduced thyroxine levels. The recommendation is that thyroid- stimulating hormone (TSH) should be monitored in people treated with levothyroxine at least the first month after starting and/or ending ritonavir treatment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">FSRH, 2019</a>] </p><!-- end field 1a2ac1db-d43c-4341-a268-91abd976c786 --><!-- end item 7ca752ba-a2f3-4bdd-8a82-c2eaea315a96 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}